CONSENSUS AND META-ANALYSESCardiovascular, renal and liver protection with novel antidiabetic agents beyond blood glucose lowering in type 2 diabetes consensus article from the European Society of Hypertension Working Group on Obesity, Diabetes and the High-risk PatientKotsis, Vasiliosa; Jordan, Jensb,c; Stabouli, Stellad; Antza, Christinaa; Micic, Dragane; Jelaković, Bojanf; Schlaich, Markus P.g,h; Nilsson, Peter M.i; Kreutz, Reinholdj,k; Mancia, Giuseppel; Tsioufis, Kostasm; Grassi, Guidon,oAuthor Information a3rd Department of Internal Medicine, Hypertension-24-h ABPM ESH Center of Excellence, Papageorgiou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece bInstitute for Aerospace Medicine, German Aerospace Center, University of Cologne cUniversity Hypertension Center, Cologne, Germany d1st Department of Pediatrics, Aristotle University of Thessaloniki, Hippokratio General Hospital, Thessaloniki, Greece eDepartment of Medical Sciences, Serbian Academy of Sciences and Arts, Belgrade, Serbia fDepartment of Nephrology, Hypertension, Dialysis and Transplantation, University Hospital Centre Zagreb, Zagreb, Croatia gDobney Hypertension Centre, School of Medicine – Royal Perth Hospital Unit, The University of Western Australia, Perth, Western Australia hNeurovascular Hypertension and Kidney Disease Laboratory, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia iDepartment of Clinical Sciences, Internal Medicine, Skåne University Hospital, Malmö, Sweden jCharité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin kInstitute of Clinical Pharmacology and Toxicology, Berlin, Germany lUniversity of Milano-Bicocca, Milan, Italy mFirst Cardiology Clinic, Medical School, National and Kapodistrian University of Athens Hippokration Hospital, Athens, Greece nClinical Medica, School of Medicine and Surgery, Milano-Bicocca University oIRCCS Multimedica, Sesto San Giovanni, Milan, Italy Correspondence to Vasilios Kotsis, MD, PhD, Hypertension-ABPM Center, Papageorgiou Hospital, Chairman WG on Obesity, Diabetes and the High Risk Patient, 39 Zaka, Panorama, 55236 Thessaloniki, Greece. Tel: +30 6974748860; fax: +30 2310452429; e-mail: firstname.lastname@example.org Abbreviations: ALT, alanine transaminase; BP, blood pressure; DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide 1; MACE, major adverse cardiac events; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; RAAS, renin–angiotensin–aldosterone system; SGLT-2, sodium–glucose cotransporter 2; T2D, type 2 diabetes Received 10 June, 2019 Revised 23 August, 2019 Accepted 16 September, 2019 Journal of Hypertension: March 2020 - Volume 38 - Issue 3 - p 377-386 doi: 10.1097/HJH.0000000000002279 Buy Metrics Abstract The prevalence of type 2 diabetes (T2D) has increased over the past few decades. T2D has a strong genetic propensity that becomes overt when a patient is exposed to a typical Western lifestyle, gain weight and becomes obese, whereas weight loss protects from the development of T2D. Except of lifestyle modifications, the choice of the appropriate treatment is essential in the management of patients with T2D and appears critical for the obese population with T2D. The new pharmacological approach for the treatment of T2D, sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists, seems to be effective not only in the management of T2D but also for weight loss, reduction of blood pressure and improvement of nonalcoholic fatty liver disease. Sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 analogues reduced cardiovascular risk, prevented cardiovascular disease and mortality, thereby playing an important role in the treatment of obese patients with hypertension and T2D. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.